Metal Mixture Toxicity to Hyalella azteca: Relationships to Body Concentrations

A literature review of metal mixture interaction analyses identified that there was not a consistent method to determine the impact of metal mixtures on an aquatic organism. The review also revealed that a majority of the research on mixtures made use of water concentrations only. Therefore research was conducted to determine the relationship between exposure, bioaccumulation and chronic effects of the four elements As, Co, Cr and Mn individually. Mechanistically based saturation models of bioaccumulation and toxicity were determined for the benthic invertebrate Hyalella azteca, from which lethal water concentrations and body concentrations were also determined. These models were then combined with those previously done for the metals Cd, Cu, Ni, Pb, Tl and Zn to model the impact of 10 metal mixtures on bioaccumulation in short term (1-week) exposures and on bioaccumulation and toxicity in chronic (4-week) exposures at “equi-toxic” concentrations. Interactions between the metals were identified in which; Cd, Co and Ni bioaccumulations were significantly inhibited, Tl and Zn bioaccumulations were marginally inhibited, there was no impact on Cr, Cu or Mn bioaccumulation, and both As and Pb bioaccumulation were enhanced by some mixtures of metals. It was determined that strict competitive inhibition may be a plausible mechanism of interaction affecting Co, Cd and Ni bioaccumulation but not for any of the other metals. However, it is possible that other interactions such as non-competitive or anti-competitive inhibition may have been responsible. A metal effects addition model (MEAM) was developed for Hyalella azteca based on both the bioaccumulation (body concentrations) to effects and the exposure (water concentration) to effects relationships developed from the single metal only studies The MEAM was used to predict the impact of metal mixture exposures on mortality. Toxicity was under-estimated when based on measured water or body concentrations, however, its best prediction was based on body concentrations. The MEAM, when based on measured body concentrations, takes bioavailability into account, which is important since the chemical characteristics of water can greatly alter the bioavailability and therefore toxicity of metals. The MEAM was compared to the traditional Concentration Addition Model (CAM), which calculates toxic units based on water concentrations and LC50s or body concentrations and LBC50s. The CAM overestimated toxicity, but had its best prediction when based on water concentrations. Over all, the best fit to observed mortality was the prediction by the MEAM, based on body concentrations. The measurement of bioaccumulated metals and the use of the MEAM could be important in field site assessments since it takes into account changes in bioavailability due to different site water chemistries whereas the traditional CAM based on water concentration does not

LETS: Lunar Environments Test System

The Environmental Effects Branch (EM50) at the Marshall Space Flight Center has developed a unique capability within the agency, namely the Lunar Environment Test System (LETS). LETS is a cryo-pumped vacuum chamber facility capable of high vacuum (10-7 Torr). LETS is a cylindrical chamber, 30 in. (0.8 m) diameter by 48 in. (1.2 m) long thermally controlled vacuum system. The chamber is equipped with a full array of radiation sources including vacuum ultraviolet, electron, and proton radiation. The unique feature of LETS is that it contains a large lunar simulant bed (18 in. x 40 in. x 6 in.) holding 75 kg of JSC-1a simulant while operating at a vacuum of 10-7 Torr. This facility allows three applications: 1) to study the charging, levitation and migration of dust particles, 2) to simulate the radiation environment on the lunar surface, and 3) to electrically charge the lunar simulant enhancing the attraction and adhesion of dust particles to test articles more closely simulating the lunar surface dust environment. LETS has numerous diagnostic instruments including TREK electrostatic probes, residual gas analyzer (RGA), temperature controlled quartz crystal microbalance (TQCM), and particle imaging velocimeter (PIV). Finally, LETS uses continuous Labview data acquisition for computer monitoring and system control

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial

Achieving glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy. To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated with insulin glargine and metformin. Phase 3, multinational, multicenter, 26-week, randomized, open-label, 2-group, treat-to-target trial conducted at 75 centers in 10 countries from September 2013 to November 2014 among 557 patients with uncontrolled diabetes treated with glargine (20-50 U) and metformin (≥1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a body mass index of 40 or lower. 1:1 randomization to degludec/liraglutide (n = 278; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or glargine (n = 279; no maximum dose), with twice-weekly titration to a glucose target of 72 to 90 mg/dL. Primary outcome measure was change in HbA1c level after 26 weeks, with a noninferiority margin of 0.3% (upper bound of 95% CI, <0.3%). If noninferiority of degludec/liraglutide was achieved, secondary end points were tested for statistical superiority and included change in HbA1c level, change in body weight, and rate of confirmed hypoglycemic episodes. Among 557 randomized patients (mean: age, 58.8 years; women, 49.7%), 92.5% of patients completed the trial and provided data at 26 weeks. Baseline HbA1c level was 8.4% for the degludec/liraglutide group and 8.2% for the glargine group. HbA1c level reduction was greater with degludec/liraglutide vs glargine (-1.81% for the degludec/liraglutide group vs -1.13% for the glargine group; estimated treatment difference [ETD], -0.59% [95% CI, -0.74% to -0.45%]), meeting criteria for noninferiority (P < .001), and also meeting criteria for statistical superiority (P < .001). Treatment with degludec/liraglutide was also associated with weight loss compared with weight gain with glargine (-1.4 kg for degludec/liraglutide vs 1.8 kg for glargine; ETD, -3.20 kg [95% CI, -3.77 to -2.64],P < .001) and fewer confirmed hypoglycemic episodes (episodes/patient-year exposure, 2.23 for degludec/liraglutide vs 5.05 for glargine; estimated rate ratio, 0.43 [95% CI, 0.30 to 0.61],P < .001). Overall and serious adverse event rates were similar in the 2 groups, except for more nonserious gastrointestinal adverse events reported with degludec/liraglutide (adverse events, 79 for degludec/liraglutide vs 18 for glargine). Among patients with uncontrolled type 2 diabetes taking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c level reduction after 26 weeks of treatment. Further studies are needed to assess longer-term efficacy and safety. clinicaltrials.gov Identifier: NCT01952145

MSFC Lunar Environments Test System (LETS) System Development

A review of the NASA MSFC Lunar Environment Test System (LETS) System Development is presented. The contents include: 1) MSFC LETS Chamber Status; 2) LETS Simulant Containment Box Development; 3) Tests Conducted in LETS To date: Simulant Dust Migration; 4) Summary; and 5) Forward Work

Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020

During April 25–29, 2020, Indiana conducted statewide random sample testing of persons aged ≥12 years to assess prevalence of active infection and presence of antibodies to SARS-CoV-2; additional nonrandom sampling was conducted in racial and ethnic minority communities to better understand the impact of the virus in certain racial and ethnic minority populations.Nir Menachemi reports a grant from State of Indiana which funded this study. Virginia Caine reports that she is a member of the MMWR Editorial Board. Brian E. Dixon and William F. Fadel report grants from the Indiana State Department of Health. Paul K. Halverson reports a grant from the State of Indiana. No other potential conflicts of interest were disclosed

Cardiovascular magnetic resonance of pulmonary artery growth and ventricular function after Norwood procedure with Sano modification

For hypoplastic left heart syndrome (HLHS), there have been concerns regarding pulmonary artery growth and ventricular dysfunction after first stage surgery consisting of the Norwood procedure modified with a right ventricle-to-pulmonary artery conduit. We report our experience using cardiovascular magnetic resonance (CMR) to determine and follow pulmonary arterial growth and ventricular function in this cohort

The Problem of Experience in the Study of Organizations

This paper deals with the fact that we cannot experience large organizations directly, in the same way as we can experience individuals or small groups, and that this non-experientiability has certain implications for our scientific theories of organizations. Whereas a science is animated by a constructive interplay of theory concepts and experience concepts, the study of organizations has been confined to theory concepts alone. Implications of this analysis for developing a science of organizations are considered.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68303/2/10.1177_017084069301400102.pd